DUBLIN–(BUSINESS WIRE)–The “Targeting
the CD47-SIRPA Axis in Oncology: Analytical Tool” report has
been added to ResearchAndMarkets.com’s offering.
Targeting the CD47-SIRPa axis is emerging as one of the most promising
new cancer immunotherapy approaches seeking to target innate immune
response. This report reveals intense global interest and a growing list
of stakeholders operating in this field. Users of this report get an
un-biased, fact driven analysis of the position of each molecule and
commercial player, always kept up to date with twice weekly updates.
This analytical tool is the must have handbook for any business
developer, BI/CI operative or clinical developer who needs to be on top
of this hot and fast moving area of immune-oncology. This unique product
is truly the only tool of its kind and is designed to give you a
competitive edge in your drug surveillance and intelligence of the
CD47-SIRPA axis in oncology, allowing you to power your decision making
and advance your own interests.
Keeping you in the know
Simply put, our mission is to fuel your knowledge of immune-oncology, to
make you the first to know about very early technologies and startups,
emerging clinical trial results, drug approvals and the ever-changing
competitive landscape.
Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool achieves this
by continuously scanning development in CD47-SIRPA axis in oncology and
reporting:
- Deals & Collaborations
-
New technologies/drugs (emerging from patents, grants, abstracts (see
Conference Coverage) etc.) - Funding/Grants/IPOs
- Filings & Approvals
- Latest Clinical Trial Development & Results
- Newly launched clinical trials
- Conference Coverage of the world’s twelve leading meetings in oncology
- Quarterly & Annual Reporting
This puts you in control of most, if not all, day-to-day developments in
your field while also benefiting from one of the most comprehensive
commercial pipeline review & competitive assessment tools available on
the market today!
Identify, prioritize, and lead scientific assessment of oncology
opportunities and competition by multiple factors such as:
- Emerging Technologies
- Target Novelty
- Recent Funding
- Early & Late Stage Pipeline
- Biomarker/Companion Diagnostic Development (featured below)
- Entered Deals & Alliances
-
Conference surveillance of world leading cancer meetings (featured
below) - Combination Therapy Choices (featured below)
- Outcome of Clinical Trials
- Indication Selection & Expansion Choices
- Drug Repositioning Opportunities
Your Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool covers
more than 70 companies and partners who are today developing 81
CD47-SIRPA axis targeting drugs where of 76 are in active development in
cancer across 28 different targets. Any data and/or analysis from the
Analytical Tool is yours to keep and data/graphs/tables can be easily
exported into Excel/PDF and various graphic formats for mixing with your
own proprietary information.
Let our expertise work for you
With a simple point and click interface you can navigate the environment
of current development, drill down into specific areas such as ongoing
combination trials, biomarker analysis, selected scientific abstracts
etc. and generate drug profiles, drug target profiles and company
profiles (including Business Development & Licensing contacts). Any
analysis generated by you is packed with presentation-ready graphs and
tables to use in your reports and presentations.
Your key to access development at the world-leading cancer
meetings
The Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool is
continuously updated according to twelve of the world’s most influential
meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR,
ESMO, SITC and BIO (International, Europe and Asia). If you are not able
to attend any of the conferences in person, this Analytical Tool ensures
that you are not missing out on the important take home messages you
need to know about.
Run combination therapy analysis like no other
The Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool delivers
comprehensive combination therapy analysis, allowing you to analyze
combination therapies from multiple perspectives; from a single drug to
virtually any cross section of oncology drugs of interest.
Unparalleled biomarker surveillance
We also provide an outstanding oncology clinical biomarker surveillance
& analysis, highlighting clinical phenotyping and patient stratification
in trials. This analysis is based on our monitoring of the presence and
usage of more than 1,000 biomarkers across tens of thousands of cancer
clinical trials.
Support and inspiration at your finger-tips
You also have access to a great selection of How-to Training Videos
showing best practice approaches to aspects such as competitive pipeline
analysis right through to many real world case examples put forward by
other users of our Analytical Tools.
A tool to grow with and keep you informed
Unlike a static report which just represents a particular snapshot in
time, all of the Analytical Tools come with one year of online access to
twice-weekly updates in both contents and features, pipeline alerts and
online support etc. You can choose to renew your access to these updates
and support on a yearly basis or go over to our industry leading full
service platform covering all oncology drug development, 1stOncology.
For more information about this report visit https://www.researchandmarkets.com/r/1joqrf
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology